Found: 35
Select item for more details and to access through your institution.
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01109-4
- By:
- Publication type:
- Article
An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.
- Published in:
- International Journal of Laboratory Hematology, 2020, v. 42, n. 2, p. e65, doi. 10.1111/ijlh.13112
- By:
- Publication type:
- Article
Physicians, paraproteins and progress: diagnosis and management of myeloma.
- Published in:
- British Journal of Hospital Medicine (17508460), 2019, v. 80, n. 2, p. 91, doi. 10.12968/hmed.2019.80.2.91
- By:
- Publication type:
- Article
The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 4, p. 1159, doi. 10.1111/bjh.19353
- By:
- Publication type:
- Article
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open‐label, randomised, phase III trial.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 2, p. 267, doi. 10.1111/bjh.18600
- By:
- Publication type:
- Article
Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 3, p. 551, doi. 10.1111/bjh.16793
- By:
- Publication type:
- Article
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 5, p. 853, doi. 10.1111/bjh.16945
- By:
- Publication type:
- Article
A real‐world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple‐myeloma patients.
- Published in:
- British Journal of Haematology, 2020, v. 191, n. 5, p. 927, doi. 10.1111/bjh.17076
- By:
- Publication type:
- Article
Impfempfehlungen beim Multiplen Myelom: ein Konsensbericht des European Myeloma Network.
- Published in:
- Kompass Onkologie, 2022, v. 9, n. 1, p. 3, doi. 10.1159/000522451
- By:
- Publication type:
- Article
A Novel Functional Role for <i>MMSET</i> in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex.
- Published in:
- PLoS ONE, 2014, v. 9, n. 6, p. 1, doi. 10.1371/journal.pone.0099493
- By:
- Publication type:
- Article
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
- Published in:
- 2022
- By:
- Publication type:
- journal article
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
- Published in:
- Nature Communications, 2015, v. 6, n. 4, p. 6997, doi. 10.1038/ncomms7997
- By:
- Publication type:
- Article
Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. e279, doi. 10.1016/j.clml.2021.10.008
- By:
- Publication type:
- Article
P-171: Multistate models provide complementary insights into outcomes for patients treated in the UK NCRI Myeloma XI randomised trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S129, doi. 10.1016/S2152-2650(21)02298-9
- By:
- Publication type:
- Article
P-144: Response to SARS-CoV-2 vaccination in patients with Multiple Myeloma using a 12-week spaced dosing strategy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S114, doi. 10.1016/S2152-2650(21)02271-0
- By:
- Publication type:
- Article
OAB-060: Prospective comparison of contemporary whole body MRI and FDG PET/CT for disease detection and correlation with markers of disease burden in myeloma: results of the iTIMM trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S37, doi. 10.1016/S2152-2650(21)02132-7
- By:
- Publication type:
- Article
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 10, p. 667, doi. 10.1016/j.clml.2021.04.013
- By:
- Publication type:
- Article
OAB-015: Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S10, doi. 10.1016/S2152-2650(21)02089-9
- By:
- Publication type:
- Article
MM-146: A Real-World Study of Bendamustine Therapy in a Very Heavily Pre-Treated Population of Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S424, doi. 10.1016/S2152-2650(21)01949-2
- By:
- Publication type:
- Article
Poster: MM-146: A Real-World Study of Bendamustine Therapy in a Very Heavily Pre-Treated Population of Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S254, doi. 10.1016/S2152-2650(21)01590-1
- By:
- Publication type:
- Article
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
A 'real-world' study of panobinostat, bortezomib and dexamethasone in a very heavily pre-treated population of myeloma patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e244, doi. 10.1016/j.clml.2019.09.405
- By:
- Publication type:
- Article
Sequential minimal residual disease (MRD) monitoring: Results from the UK Myeloma XI trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e45, doi. 10.1016/j.clml.2019.09.069
- By:
- Publication type:
- Article
Quadruplet KCRD (Carfilzomib, Cyclophosphamide, Lenalidomide and Dexamethasone) Induction for Newly Diagnosed Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e2, doi. 10.1016/j.clml.2019.09.003
- By:
- Publication type:
- Article
Neutral Tumor Evolution in Myeloma is Associated With Poor Response to Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e10, doi. 10.1016/j.clml.2017.03.017
- By:
- Publication type:
- Article
The Impact of Maintenance Lenalidomide and Depth of Response on the Mutational Status of the Myeloma Clone from Presentation to Relapse.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e100, doi. 10.1016/j.clml.2017.03.181
- By:
- Publication type:
- Article
Integrating Molecular Genetic and Gene Expression Profiling Allows Stratification of Ultra-High Risk Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e1, doi. 10.1016/j.clml.2017.03.003
- By:
- Publication type:
- Article
Retrospective Cohort Analysis Examining the Efficacy and Safety of (V)DTPACE in Newly Diagnosed and Relapsed/Refractory Myeloma Patients – the UK Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S80, doi. 10.1016/j.clml.2016.07.112
- By:
- Publication type:
- Article
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00779-2
- By:
- Publication type:
- Article
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 2, p. 291, doi. 10.1111/bjh.12218
- By:
- Publication type:
- Article
Crystalline keratopathy associated with monoclonal gammopathy of undetermined significance.
- Published in:
- British Journal of Haematology, 2012, v. 159, n. 3, p. 258, doi. 10.1111/bjh.12047
- By:
- Publication type:
- Article
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 2, p. 696, doi. 10.1007/s12325-023-02738-0
- By:
- Publication type:
- Article
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 5, p. 2412, doi. 10.1007/s12325-023-02480-7
- By:
- Publication type:
- Article
Nuances in the Management of Older People With Multiple Myeloma.
- Published in:
- Current Hematologic Malignancy Reports, 2016, v. 11, n. 3, p. 241, doi. 10.1007/s11899-016-0323-4
- By:
- Publication type:
- Article